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OBJECTIVE:
 
 To evaluate the impact of amlodipine
treatment on hospital utilization and costs.
 
METHODS:
 
 Hospital record data from the PRAISE
study were analyzed for 421 patients (amlodipine, 209;
placebo, 212) with nonischemic heart failure. Reason for
admission was encoded according to the ICD-9-CM and
a diagnosis related group (DRG) was assigned. Hospital-
ization costs were estimated from a DRG-based per-diem
cost of hospitalization multiplied by hospital length of
stay. Cost of amlodipine therapy was estimated from the
average wholesale price at the end of the study.
RESULTS: Treatment with amlodipine versus placebo
significantly delayed time to first hospitalization (447 
26 days versus 315  18 days [means  standard errors];
p  0.0139). Although both treatment groups showed a
similar number of hospital admissions per patient per
year (1.33  0.17 [amlodipine] versus 1.41  0.13 [pla-
cebo]; p  0.72), amlodipine showed a trend toward re-
duced hospital length of stay and costs (hospitalization
1.17 days less per year [p  0.13] than placebo at a cost
of $1098 less per person per year [p  0.09]). In addi-
tion, significantly fewer amlodipine patients were admit-
ted for unexplained cardiac arrest and ventricular ar-
rhythmias (odds ratio 0.497 [p  0.004]).
CONCLUSIONS: This analysis suggests that, in patients
with nonischemic heart failure, treatment with amlodipine
can delay time to hospitalization after starting treatment,
may reduce overall hospital utilization and costs, and may
reduce admissions related to ventricular arrhythmias. The
estimated reduction of $1098 per year in hospital costs
would more than offset the amlodipine treatment cost of
approximately $700 per year.
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TRANSLUMINAL CORONARY ANGIOPLASTY: 
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Morton D
University HealthSystem Consortium, Oak Brook, IL, USA
OBJECTIVES: To study the glycoprotein IIb/IIIa inhibi-
tor abciximab (AB) in the actual use (uncontrolled) set-
ting.
METHODS: The study evaluated 291 patients who did
(n  145) or did not (n  146) receive AB as adjunct
treatment for PTCA at eight US academic centers. Based
on product labeling, all patients were eligible to receive
AB. Data came from hospital records and 6-month fol-
low-up interviews.
RESULTS: Most patients (87%) were treated by physi-
cians who chose AB in some but not others. Previous MI
(by history or as PTCA indication) and urgent admission
status were more common (p  0.05) in the AB group,
while angina unresponsive to medical therapy (ANGU)
and restenosis as indications for the PTCA were more
common (p  0.05) in the non-AB group. Bleeding and
other complications were comparable between the two
groups. Six-month data were: AB (n  145), No AB (n 
146) and P-value where Deaths were 6, 2, NS; Non-Fatal
MI were 12, 12, NS; Revascularization were 25, 23, NS;
and Other Cardiac Hospitalization were 17, 29, 0.057,
respectively. ANGU (OR, 2.26, p  0.02) and AB and
stents (OR, 0.61, p  0.04) affected other cardiac hospi-
talizations (e.g., CHF, arrhythmia). The combination of
AB and stents seemed to provide the best results for pre-
venting other cardiac hospitalizations.
CONCLUSION: Within labeled indications, physicians
seemed to select AB use based on certain patient charac-
teristics. The number of patients requiring subsequent
cardiac-related hospitalizations after 6 months tended to
be less in the abciximab-treated patients providing eco-
nomic offsets. Further studies are warranted to validate
these observations and the implications for healthcare re-
imbursement and practice guidelines.
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